FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

Lilly Filing NDA for Expanded Tirzepatide Use

Eli Lilly plans to file an NDA mid-year for tirzepatide and its use in treating obstructive sleep apnea; the drug is currently marketed as Zepbound fo...

latest-news-card-1
Human Drugs

Restrictions on Lutathera ANDA Sought

Novartis asks FDA to impose limits on applications for generic forms of its Lutathera radioligand.

latest-news-card-1
Human Drugs

Sun Pharma Hit With 483 After India Inspection

FDA issues Sun Pharmaceutical Industries a six-item Form-483 following a two-week December inspection at the firms Dadra, Dadra & Nagar Haveli and Dam...

latest-news-card-1
Medical Devices

Soulaire Marketing Unapproved Device: FDA

FDA warns Soulaire Corp. that it is marketing an external counterpulsation system for unapproved uses, adulterating and misbranding the unit.

latest-news-card-1
Human Drugs

2 CGMP Violations in Natco Pharma Inspection

FDA warns the Telangana, India-based Natco Pharma manufacturing facility about CGMP violations in its production of finished drugs.

latest-news-card-1
Federal Register

Clinical Trial Innovation Center Established

CDER establishes the Center for Clinical Trial Innovation to support innovative approaches to clinical trials that are designed to improve the quality...

latest-news-card-1
Medical Devices

Ex-CEO Sentenced Over Phony Covid Test

A federal court sentences former Decision Diagnostics CEO Keith Berman to seven years in prison for a securities fraud scheme involving a Covid-detect...

latest-news-card-1
Human Drugs

FDA Warns on Suspected Counterfeit Botox

FDA issues a safety alert on unsafe counterfeit versions of AbbVies Botox (botulinum toxin) have been found in multiple states and administered to con...

latest-news-card-1
Medical Devices

Xstim Spine Fusion Stimulator Approved

FDA approves an Xstim PMA for the Xstim Spine Fusion Stimulator for bone growth stimulation.

latest-news-card-1
Human Drugs

CBER Joining Lupus Research Consortium

FDA adds CBER to its partnership with the Lupus Accelerating Breakthroughs Consortium to better focus on engineered cell therapies.